In prostate cancer, IGF-1 induced survivin expression via activation of the mTOR/p70S6K axis, leading to increased translation of pre-existing survivin mRNA; this process was inhibited by introduction of a p70S6K siRNA and by the mTOR inhibitor rapamycin (18). Here, MTOR is linked to prostate cancer.